Longeveron (NASDAQ:LGVN) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Longeveron (NASDAQ:LGVN) from a hold rating to a sell rating in a report published on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Longeveron in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Longeveron presently has an average rating of “Hold” and an average target price of $3.00.

Longeveron Stock Performance

Shares of LGVN stock opened at $0.85 on Friday. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.03. Longeveron has a 52 week low of $0.48 and a 52 week high of $1.80. The stock has a market capitalization of $19.80 million, a PE ratio of -0.66 and a beta of -0.31. The firm has a 50 day moving average of $0.89 and a two-hundred day moving average of $0.72.

Longeveron (NASDAQ:LGVN) last issued its quarterly earnings results on Tuesday, March 17th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.20. Longeveron had a negative net margin of 1,893.58% and a negative return on equity of 199.79%. The company had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $0.11 million. On average, research analysts predict that Longeveron will post -0.62 EPS for the current fiscal year.

Institutional Investors Weigh In On Longeveron

A hedge fund recently bought a new stake in Longeveron stock. XTX Topco Ltd acquired a new position in shares of Longeveron Inc. (NASDAQ:LGVN) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned about 0.32% of Longeveron at the end of the most recent quarter. Hedge funds and other institutional investors own 10.01% of the company’s stock.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.